If Virtual Health Care Is the Future, Then This TSX Stock Is a Screaming Buy

Here’s why I think Dialogue Health (TSX:CARE) is an intriguing growth option for investors to consider right now.

| More on:
healthcare pharma

Image source: Getty Images

The telemedicine sector is red hot right now. Indeed, the innovation this sector provides has been necessary as a result of the pandemic.

However, for those banking on the long term, this sector could be a great one to invest in right now. Pandemic-friendly stocks are selling off right now. For those who believe in a telemedicine-oriented future, now’s the time to buy.

One of the newer entrants onto the TSX, Dialogue Health (TSX:CARE) is an intriguing option in this space. Here’s more on what this company does and why I think it’s an interesting pick today.

High demand driving growth

The pandemic resulted in a surge in patient demand for telemedicine solutions. Many doctors’ offices simply wouldn’t let patients come in for various reasons. Being able to treat non-acute medical issues via a virtual modality is something that has become second nature to many healthcare providers and patients of late.

It wasn’t always this way. The healthcare sector is one that hasn’t changed much over the past century. It’s a sector that’s traditionally been difficult to innovate in. Companies like Dialogue Health are re-shaping this argument.

Surging demand and regulatory requirements combined to provide the perfect tailwind for Dialogue to go public. Since going public, this stock has waned, trading nearly 40% below its all-time high. This comes despite rather bullish numbers released by the company of late.

Dialogue’s virtual platform features a lucid user interface and a well-organized architecture. These have been instrumental in expanding this company’s large customer base. This is a 24/7 multi service hub with more than 2,000 direct customers and 50,000 customers via its various partnerships. Dialogue links individuals with over 500 multifaceted healthcare providers across a number of clinical specialties in primary and mental health care.

Analysts are bullish on Dialogue 

After Dialogue became listed on the TSX on March 30, David Newman, an analyst at Desjardins Securities, initiated coverage of the company. He’s bullish on this stock owing to different factors, which he pointed out in his recent research report.

These include Dialogue’s excellent position in the virtual care space, and the company’s focus on the B2B market, which is currently poised for disruption. This company has an ideal business model, which has ensured a high customer-retention rate. Moreover, Dialogue has displayed strong revenue generation consistently.

Furthermore, Dialogue’s advanced platform is one that’s highly scalable. With an efficient management team steering the ship, many expect this company to produce some impressive growth long-term. This growth could potentially be supplemented by additional M&A activity over the medium term.

Bottom line

Undoubtedly, there appears to be a tonne of upside for Dialogue, as it continues to implement its effective strategy to build its one-of-a-kind Integrated Health Platform. It certainly has the potential to grow its operations and extend its offering to new locations via strategic acquisitions.

I believe that Dialogue is well positioned to disrupt a sector that many believed as impossible to penetrate. Accordingly, this company represents the innovation of the future.

Indeed, that’s something every long-term investor can get behind.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned.

More on Investing

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

CPP Insights: The Average Benefit at Age 60 in 2024

The average CPP benefit at age 60 in average is low, but claiming early has many advantages with the right…

Read more »

edit Sale sign, value, discount
Investing

2 Bargains I’d Buy as They Dip Toward 52-Week Lows

Spin Master (TSX:TOY) stock and another underrated Canadian play could surge again as they look to reverse course.

Read more »

thinking
Dividend Stocks

Why Did goeasy Stock Jump 6% This Week?

The spring budget came in from our federal government, and goeasy stock (TSX:GSY) investors were incredibly pleased by the results.

Read more »

woman analyze data
Dividend Stocks

My Top 5 Dividend Stocks for Passive-Income Investors to Buy in April 2024

These five TSX dividend stocks can help you create a passive stream of dividend income for life. Let's see why.

Read more »

investment research
Stocks for Beginners

New Investors: 5 Top Canadian Stocks for 2024

Here are five Canadian stocks that might be ideal for a beginner investment portfolio.

Read more »

Pipeline
Energy Stocks

Here Is Why Enbridge Is a No-Brainer Dividend Stock

For investors looking for a no-brainer dividend stock worth holding for the long term, here's why Enbridge (TSX:ENB) should be…

Read more »

Dots over the earth connecting the world
Tech Stocks

Hot Takeaway: Concentration in 1 Stock Can Be Just Fine

Concentration in one stock can be alright under the right circumstances, and far better than buying a bunch of poor-performing…

Read more »

grow money, wealth build
Bank Stocks

TD Bank Stock Got Upgraded, and It’s a Good Time to Load Up

TD Bank (TSX:TD) stock is getting too cheap, even for analysts at the competing banks!

Read more »